The role of systemic and targeted therapies in brain metastases

For many years, brain metastases (BMs) have been considered as the final stage of a disease course and engendered skepticism about the efficacy of treatments. Local treatments, mainly, whole-brain radiotherapy have been the standard of care, whereas chemotherapy has been considered of limited efficacy due to the potential role of blood–brain barrier.